Valerie K Sullivan1,2, Lawrence J Appel1,2,3, Jesse C Seegmiller4, Scott T McClure5, Casey M Rebholz1,2. 1. Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD, USA. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 3. Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA. 5. Department of Public Health, College of Arts and Sciences, Shenandoah University, Winchester, VA, USA.
Abstract
BACKGROUND: The blood pressure-lowering effects of the Dietary Approaches to Stop Hypertension (DASH) dietary pattern and reduced sodium intake are well established. The effects on other biomarkers related to vascular health are of interest and might assist in explaining the effects of the DASH diet and sodium reduction. OBJECTIVES: We hypothesized that a low-sodium DASH diet improves (lowers) biomarkers of inflammation [C-reactive protein (CRP) and soluble urokinase plasminogen activator receptor (suPAR)] and mineral metabolism [phosphorus and fibroblast growth factor-23 (FGF23)]. METHODS: We conducted a secondary analysis of the DASH-Sodium trial using frozen serum samples. This controlled feeding study randomly assigned 412 adults (≥22 y) with elevated blood pressure (120-159/80-95 mmHg) to consume either a DASH diet or control diet. Within each arm, participants received 3 sodium levels [low (1150 mg), intermediate (2300 mg), high (3450 mg)] in random sequence, each for 30 d. To maximize contrast, samples collected at the end of the low-sodium DASH (n = 198) and high-sodium control (n = 194) diets were compared. Between-diet differences in serum CRP, suPAR, phosphorus, and FGF23 concentrations were assessed using linear regression adjusted for age, sex, race, income, education, smoking status, and BMI. RESULTS: CRP concentrations did not differ between groups (P = 0.83), but suPAR was higher after the low-sodium DASH diet than the high-sodium control [geometric mean 2470 pg/mL (95% CI: 2380, 2560 pg/mL), compared with 2290 pg/mL (95% CI: 2210, 2380 pg/mL); P = 0.006]. Phosphorus was higher after the low-sodium DASH diet [geometric mean 3.50 mg/dL (95% CI: 3.43, 3.57 mg/dL)] compared with the high-sodium control diet [geometric mean 3.39 mg/dL (95% CI: 3.33, 3.46 mg/dL); P = 0.04]. FGF23 was also higher after the low-sodium DASH diet [geometric mean 35.3 pg/mL (95% CI: 33.3, 37.3 pg/mL) compared with 28.2 pg/mL (95% CI: 26.6, 29.8 pg/mL); P < 0.001]. CONCLUSIONS: Contrary to our hypothesis, biomarkers of inflammation and mineral metabolism were increased or unchanged by a low-sodium DASH diet compared with a high-sodium control diet in adults with elevated blood pressure.
BACKGROUND: The blood pressure-lowering effects of the Dietary Approaches to Stop Hypertension (DASH) dietary pattern and reduced sodium intake are well established. The effects on other biomarkers related to vascular health are of interest and might assist in explaining the effects of the DASH diet and sodium reduction. OBJECTIVES: We hypothesized that a low-sodium DASH diet improves (lowers) biomarkers of inflammation [C-reactive protein (CRP) and soluble urokinase plasminogen activator receptor (suPAR)] and mineral metabolism [phosphorus and fibroblast growth factor-23 (FGF23)]. METHODS: We conducted a secondary analysis of the DASH-Sodium trial using frozen serum samples. This controlled feeding study randomly assigned 412 adults (≥22 y) with elevated blood pressure (120-159/80-95 mmHg) to consume either a DASH diet or control diet. Within each arm, participants received 3 sodium levels [low (1150 mg), intermediate (2300 mg), high (3450 mg)] in random sequence, each for 30 d. To maximize contrast, samples collected at the end of the low-sodium DASH (n = 198) and high-sodium control (n = 194) diets were compared. Between-diet differences in serum CRP, suPAR, phosphorus, and FGF23 concentrations were assessed using linear regression adjusted for age, sex, race, income, education, smoking status, and BMI. RESULTS: CRP concentrations did not differ between groups (P = 0.83), but suPAR was higher after the low-sodium DASH diet than the high-sodium control [geometric mean 2470 pg/mL (95% CI: 2380, 2560 pg/mL), compared with 2290 pg/mL (95% CI: 2210, 2380 pg/mL); P = 0.006]. Phosphorus was higher after the low-sodium DASH diet [geometric mean 3.50 mg/dL (95% CI: 3.43, 3.57 mg/dL)] compared with the high-sodium control diet [geometric mean 3.39 mg/dL (95% CI: 3.33, 3.46 mg/dL); P = 0.04]. FGF23 was also higher after the low-sodium DASH diet [geometric mean 35.3 pg/mL (95% CI: 33.3, 37.3 pg/mL) compared with 28.2 pg/mL (95% CI: 26.6, 29.8 pg/mL); P < 0.001]. CONCLUSIONS: Contrary to our hypothesis, biomarkers of inflammation and mineral metabolism were increased or unchanged by a low-sodium DASH diet compared with a high-sodium control diet in adults with elevated blood pressure.
Authors: Paul M Ridker; Brendan M Everett; Aruna Pradhan; Jean G MacFadyen; Daniel H Solomon; Elaine Zaharris; Virak Mam; Ahmed Hasan; Yves Rosenberg; Erin Iturriaga; Milan Gupta; Michelle Tsigoulis; Subodh Verma; Michael Clearfield; Peter Libby; Samuel Z Goldhaber; Roger Seagle; Cyril Ofori; Mohammad Saklayen; Samuel Butman; Narendra Singh; Michel Le May; Olivier Bertrand; James Johnston; Nina P Paynter; Robert J Glynn Journal: N Engl J Med Date: 2018-11-10 Impact factor: 91.245
Authors: Joachim H Ix; Ronit Katz; Bryan R Kestenbaum; Ian H de Boer; Michel Chonchol; Kenneth J Mukamal; Dena Rifkin; David S Siscovick; Mark J Sarnak; Michael G Shlipak Journal: J Am Coll Cardiol Date: 2012-06-13 Impact factor: 24.094
Authors: Stig Lyngbæk; Jacob L Marott; Thomas Sehestedt; Tine W Hansen; Michael H Olsen; Ove Andersen; Allan Linneberg; Steen B Haugaard; Jesper Eugen-Olsen; Peter R Hansen; Jørgen Jeppesen Journal: Int J Cardiol Date: 2012-08-19 Impact factor: 4.164
Authors: Peter Bogaty; Gilles R Dagenais; Lawrence Joseph; Luce Boyer; Anne Leblanc; Patrick Bélisle; James M Brophy Journal: PLoS One Date: 2013-04-08 Impact factor: 3.240
Authors: Stephen Kaptoge; Emanuele Di Angelantonio; Gordon Lowe; Mark B Pepys; Simon G Thompson; Rory Collins; John Danesh Journal: Lancet Date: 2009-12-22 Impact factor: 79.321
Authors: Elizabeth D Drugge; Khalid Farhan; Hong Zhao; Rozalia Abramov; Lesley A Graham; Nancy Stambler; Shoujin Hao; Nicholas R Ferreri Journal: J Hum Hypertens Date: 2022-08-25 Impact factor: 2.877